NO20014105D0 - Texanderivater for malrettet kreftterapi - Google Patents

Texanderivater for malrettet kreftterapi

Info

Publication number
NO20014105D0
NO20014105D0 NO20014105A NO20014105A NO20014105D0 NO 20014105 D0 NO20014105 D0 NO 20014105D0 NO 20014105 A NO20014105 A NO 20014105A NO 20014105 A NO20014105 A NO 20014105A NO 20014105 D0 NO20014105 D0 NO 20014105D0
Authority
NO
Norway
Prior art keywords
texan
derivatives
cancer therapy
targeted cancer
targeted
Prior art date
Application number
NO20014105A
Other languages
English (en)
Other versions
NO20014105L (no
Inventor
Ahmad Safavy
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of NO20014105D0 publication Critical patent/NO20014105D0/no
Publication of NO20014105L publication Critical patent/NO20014105L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20014105A 1999-02-24 2001-08-23 Texanderivater for målrettet cancerterapi NO20014105L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12164299P 1999-02-24 1999-02-24
PCT/US2000/004551 WO2000050059A1 (en) 1999-02-24 2000-02-23 Taxane derivatives for targeted therapy of cancer

Publications (2)

Publication Number Publication Date
NO20014105D0 true NO20014105D0 (no) 2001-08-23
NO20014105L NO20014105L (no) 2001-10-11

Family

ID=22397942

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014105A NO20014105L (no) 1999-02-24 2001-08-23 Texanderivater for målrettet cancerterapi

Country Status (8)

Country Link
US (1) US6191290B1 (no)
EP (1) EP1154782A4 (no)
JP (1) JP4808846B2 (no)
AU (1) AU768027B2 (no)
CA (1) CA2362937C (no)
MX (1) MXPA01008699A (no)
NO (1) NO20014105L (no)
WO (1) WO2000050059A1 (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000504692A (ja) * 1996-02-08 2000-04-18 アフトン・コーポレーション 胃腸癌治療用の免疫学的方法
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
ES2227833T3 (es) * 1997-05-12 2005-04-01 Aphton Corporation Composiciones inmunogenicas para el receptor cck-b/gastrina y metodos para el tratamiento de tumores.
JP2002515458A (ja) * 1998-05-15 2002-05-28 アフトン・コーポレーシヨン 高ガストリン血症の予防および処置
ATE349438T1 (de) 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
CA2441484A1 (en) * 2001-03-23 2002-10-03 Napro Biotherapeutics, Inc. Molecular conjugates for use in treatment of cancer
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
CA2450898A1 (en) * 2001-07-09 2003-01-23 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
WO2003035011A2 (en) * 2001-10-26 2003-05-01 The Uab Research Foundation Multidrug multiligand conjugates for targeted drug delivery
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
US20080025981A1 (en) * 2002-03-04 2008-01-31 Young Paul E Cancer-linked genes as targets for chemotherapy
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
CN100522955C (zh) 2002-08-02 2009-08-05 伊缪诺金公司 含有新型强效紫杉烷的细胞毒性剂及其治疗用途
US7981928B2 (en) 2002-09-05 2011-07-19 Nanodynamics, Inc. Chemotherapy method using x-rays
JP4903036B2 (ja) * 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
US7611692B2 (en) 2003-01-13 2009-11-03 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7850947B2 (en) 2003-01-13 2010-12-14 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US8420050B2 (en) 2003-01-13 2013-04-16 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7922998B2 (en) 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US20060239923A1 (en) * 2003-01-13 2006-10-26 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
CA2520010C (en) * 2003-03-28 2012-07-10 Aphton Corporation Gastrin hormone immunoassays
AU2004232314B2 (en) * 2003-04-22 2007-11-22 Ipsen Pharma S.A.S. Peptide vectors
JP2008513536A (ja) * 2004-09-22 2008-05-01 レセプター バイオロジックス インコーポレイテッド プロガストリンに対するモノクローナル抗体
WO2006060664A2 (en) * 2004-12-03 2006-06-08 The Uab Research Foundation Single-drug multi-ligand conjugates for targeted drug delivery
DK2360258T3 (en) * 2005-02-18 2015-01-12 Angiochem Inc Aprotininpolypeptider to transport a compound of blood-brain-barrier
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
EP1907009A4 (en) * 2005-07-15 2009-09-02 Angiochem Inc USE OF APROTININ POLYPEPTIDES AS CARRIER IN PHARMACEUTICAL CONJUGATES
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US20110262354A1 (en) 2007-07-13 2011-10-27 Emory University Cyanine-containing compounds for cancer imaging and treatment
DK2279008T3 (en) * 2008-04-18 2019-04-29 Angiochem Inc PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGS OR PACLITAXEL CONJUGATES AND RELATED PROCEDURES FOR PREPARATION AND USE
WO2009152440A1 (en) * 2008-06-13 2009-12-17 Cedars-Sinai Medical Center Small molecule ligand-drug conjugates for targeted cancer therapy
RU2531591C2 (ru) 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
CN102245642A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 Glp-1激动剂的结合物及其用途
AU2009322043A1 (en) 2008-12-05 2011-07-07 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
CA2759129C (en) 2009-04-20 2018-12-11 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
RU2604718C2 (ru) 2010-05-27 2016-12-10 Шэньчжэнь Салубрис Фармасьютикалз Ко.,Лтд. Химический синтез и противоопухолевый и противометастатический эффекты конъюгата двойного действия
EP2717699B1 (en) 2011-06-06 2020-06-03 Veiled Therapeutics LLC Acid-labile lipophilic prodrugs of chemo-therapeutic anti-cancer agents
CN108686203A (zh) 2012-04-04 2018-10-23 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
CA3066756A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
CN109999202B (zh) * 2019-01-18 2022-03-22 南阳师范学院 一种介导紫杉醇递送的多功能肽及其应用
KR20240022567A (ko) 2021-06-16 2024-02-20 베일드 세러퓨틱스 엘엘씨 암의 치료를 위한 산-불안정 화학요법 파클리탁셀 기반 화합물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
AU6267896A (en) * 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
CA2264227A1 (en) * 1996-09-27 1998-04-02 Raymond A. Firestone Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
CA2264610A1 (en) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Branched peptide linkers
EP1033372A4 (en) * 1997-11-18 2000-10-04 Chugai Pharmaceutical Co Ltd COMPOSITIONS WITH ANTI-TUMOR ACTIVITY
ATE349438T1 (de) * 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
AU2001244602A1 (en) * 2000-03-30 2001-10-15 Ajinomoto Co. Inc. Drugs retained in target tissue over long time
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use

Also Published As

Publication number Publication date
EP1154782A1 (en) 2001-11-21
AU3499600A (en) 2000-09-14
CA2362937A1 (en) 2000-08-31
US6191290B1 (en) 2001-02-20
MXPA01008699A (es) 2002-06-21
JP4808846B2 (ja) 2011-11-02
EP1154782A4 (en) 2002-09-25
WO2000050059A1 (en) 2000-08-31
JP2002537347A (ja) 2002-11-05
CA2362937C (en) 2011-03-22
NO20014105L (no) 2001-10-11
AU768027B2 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
NO20014105D0 (no) Texanderivater for malrettet kreftterapi
LTPA2020503I1 (lt) Rapamicino darinys, skirtas kasos vėžio gydymui
NO20021400D0 (no) Terapeutiske konazolinderivater
DE60009147D1 (de) Admantan derivate
EE200200673A (et) Kinasoliini derivaadid kasvajate raviks
DK1637127T3 (da) Terapeutisk mikroskum
IS2277B (is) Meðferðarlegar bíarýl afleiður
DE60010448D1 (de) Amid-derivate
IS7670A (is) Samsett meðferð fyrir offjölgunar sjúkdóma
EP1212057A4 (en) LONG-TERM PHOTODYNAMIC TREATMENT OF CANCER
DE60013127D1 (de) 5-phenyl-pyrimidine derivate
NO20024775L (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamid derivater til behandling avsmerte
DE60019864D1 (de) Lasertherapiegerät
NO20020358D0 (no) Anvendelse av etodolac for behandling av kreft
NO20006047L (no) Fremgangsmåte for genterapi
DE60025918D1 (de) 4-phenyl-pyrimidine derivate
ATE254598T1 (de) 4-hydroxybiphenylhydrazid-derivate
DK1165071T3 (da) Forbedret cancerbehandling med temozolomid
NO20023971D0 (no) Hormonterapi ved brystcancer
NO20014660L (no) Ledekile-Fòringsrörfresesystem
NO20021976L (no) Selektiv leverterapi
DE50009678D1 (de) Schädlingsbekämpfungsmittel/pf 1022-221
NO20020951D0 (no) Fremgangsmåte for multimodul kryptering
FIU990263U0 (fi) Rapuneula
ITCZ990004A0 (it) Apparecchio per auricolo terapia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application